Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18857012 | 0.87 | TAAR1 (0.52) | TAAR1HTR2AALDH1A1HPGDALOX15 | |
| SCHEMBL5733248 | 0.85 | TAAR1 (0.50) | TAAR1HTR2AALDH1A1HPGDALOX15 | |
| SCHEMBL626076 | 0.84 | TAAR1 (0.68) | TAAR1HTR2AALDH1A1ALOX15CYP2A6 | |
| SCHEMBL10685072 | 0.84 | ALDH1A1 (0.69) | TAAR1HTR2AALDH1A1HPGDALOX15 | |
| SCHEMBL11402440 | 0.83 | TAAR1 (0.48) | TAAR1HTR2AALDH1A1HPGDALOX15 | |
| SCHEMBL1046235 | 0.80 | TAAR1 (0.56) | TAAR1HTR2ACYP2A6IDO1GSK3B | |
| SCHEMBL374707 | 0.79 | — | — | |
| SCHEMBL7904900 | 0.79 | TAAR1 (0.62) | TAAR1HTR2ACYP2A6IDO1 | |
| SCHEMBL5238701 | 0.79 | TAAR1 (0.62) | TAAR1HTR2ACYP2A6IDO1 | |
| SCHEMBL127492 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-09 | — | — | US | disclosed |
| CN-113880737-B | Application of novel persulfate reagent in synthesis of asymmetric polysulfide | 安徽农业大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-116332711-A | Application of bilateral disulfide reagent in stepwise synthesis of asymmetric disulfide | 安徽农业大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-111087359-B | Preparation method of Iguratimod | 中国医学科学院药物研究所 | 2022-06-21 | — | — | CN | disclosed |
| CN-111087358-B | Preparation method of Prisamod | 中国医学科学院药物研究所 | 2022-06-21 | — | — | CN | disclosed |
| CN-111087356-B | Preparation method of Iguratimod | 中国医学科学院药物研究所 | 2022-06-21 | — | — | CN | disclosed |
| CN-113880737-A | Application of novel persulfur reagent in synthesis of asymmetric persulfur | 安徽农业大学 | 2022-01-04 | — | — | CN | disclosed |
| CN-111087359-A | Preparation method of Iguratimod | 中国医学科学院药物研究所 | 2020-05-01 | — | — | CN | disclosed |
| CN-111087356-A | Preparation method of Iguratimod | 中国医学科学院药物研究所 | 2020-05-01 | — | — | CN | disclosed |
| CN-111087358-A | Preparation method of Prisamod | 中国医学科学院药物研究所 | 2020-05-01 | — | — | CN | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| WO-2009019015-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019005-A2 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | disclosed |
| WO-2005014525-A2 | BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY | MITSUBISHI PHARMA CORPORATION (JP) | 2005-02-17 | — | — | WO | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | NISCH, COASY, KLK7 | TAAR1 4559/4885HTR2A 4756/4885ALDH1A1 1924/4885 |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | ADRB2, ADRB1, ADRB3 | TAAR1 341/4885HTR2A 517/4885ALDH1A1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.